{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:43:34Z","timestamp":1790761414023,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives de P\u00e9diatrie"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.arcped.2014.10.011","type":"journal-article","created":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T06:06:38Z","timestamp":1415081198000},"page":"92-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Am\u00e9liorer la surveillance de la tol\u00e9rance p\u00e9diatrique des antipsychotiques en France"],"prefix":"10.1016","volume":"22","author":[{"given":"M.-L.","family":"Menard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Askenazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Auby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bonnot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcped.2014.10.011_bib0005","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1542\/peds.2007-2008","article-title":"Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom","volume":"121","author":"Rani","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.arcped.2014.10.011_bib0010","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1176\/ps.2008.59.5.554","article-title":"Use of antipsychotic drugs among Dutch youths between 1997 and 2005","volume":"59","author":"Kalverdijk","year":"2008","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.arcped.2014.10.011_bib0015","first-page":"1","article-title":"Child and adolescent psychiatry and mantal health","volume":"26","author":"Zito","year":"2008","journal-title":"Child Adolesc Psychiatry Mant Health"},{"key":"10.1016\/j.arcped.2014.10.011_bib0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1185\/030079906X158075","article-title":"Patterns and determinants of antipsychotic prescribing in children and adolescents 2003\u20132004","volume":"23","author":"Aparasu","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.arcped.2014.10.011_bib0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ambp.2005.11.002","article-title":"Trends in prescribing of antipsychotic medications for US children","volume":"6","author":"Cooper","year":"2006","journal-title":"Ambul Pediatr"},{"key":"10.1016\/j.arcped.2014.10.011_bib0030","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archpsyc.63.6.679","article-title":"National trends in the outpatient treatment of children and adolescents with antipsychotic drugs","volume":"63","author":"Olfson","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.arcped.2014.10.011_bib0035","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neurenf.2011.04.007","article-title":"Nouveaux enjeux de la recherche clinique en psychopharmacologie chez l\u2019enfant et l\u2019adolescent","volume":"60","author":"Auby","year":"2012","journal-title":"Neuropsychiatr Enfance Adolesc"},{"key":"10.1016\/j.arcped.2014.10.011_bib0040","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.arcped.2009.06.012","article-title":"Utilisation hors autorisation de mise sur le march\u00e9 (AMM) des psychotropes en p\u00e9diatrie\u00a0: une \u00e9tude prospective","volume":"16","author":"Winterfeld","year":"2009","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.arcped.2014.10.011_bib0045","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00787-009-0749-5","article-title":"Olanzapine compared to quetiapine in adolescents with a first psychotic episode","volume":"18","author":"Arango","year":"2009","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.arcped.2014.10.011_bib0050","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.euroneuro.2009.04.008","article-title":"Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns","volume":"19","author":"Vitiello","year":"2009","journal-title":"Eur Neuropsychopharmocol"},{"key":"10.1016\/j.arcped.2014.10.011_bib0055","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/09540260801889179","article-title":"Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients","volume":"20","author":"Correll","year":"2008","journal-title":"Int Rev Psychiatry"},{"key":"10.1016\/j.arcped.2014.10.011_bib0060","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.chi.0000220851.94392.30","article-title":"Endocrine and metabolic adverse effects of psychotic medications in children and adolescents","volume":"45","author":"Correll","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.arcped.2014.10.011_bib0065","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/00004583-200212000-00015","article-title":"Effects of development on olanzapine associated adverse events","volume":"41","author":"Woods","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.arcped.2014.10.011_bib0070","series-title":"Suivi cardiom\u00e9tabolique des patients traits par antipsychotiques","author":"HAS","year":"2010"},{"key":"10.1016\/j.arcped.2014.10.011_bib0075","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.npp.1300327","article-title":"A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8\u00a0week trial","volume":"29","author":"Sikich","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.arcped.2014.10.011_bib0080","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/01.chi.0000095540.18151.b0","article-title":"Aripiprazole and extrapyramidal symptoms","volume":"42","author":"Lindsey","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.arcped.2014.10.011_bib0085","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/cap.2004.14.593","article-title":"The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review","volume":"14","author":"Barzman","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.arcped.2014.10.011_bib0090","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00004583-199802000-00016","article-title":"Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia","volume":"37","author":"Kumra","year":"1998","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.arcped.2014.10.011_bib0095","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/cap.2006.0117","article-title":"One year incidence rates of tardive dyskinesia in children and adolescents treated with second generation antipsychotics: a systematic review","volume":"17","author":"Correll","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.arcped.2014.10.011_bib0100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/cap.2008.1821","article-title":"Atypical neuroleptic malignant syndrome in an adolescent","volume":"18","author":"Rais","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.arcped.2014.10.011_bib0105","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1089\/cap.2008.18502","article-title":"Psychosis or atypical neuroleptic malignant syndrome in an adolescent?","volume":"18","author":"Groff","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.arcped.2014.10.011_bib0110","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","article-title":"Metabolic and endocrine adverse effects of second generation antipsychotics in children and adolescents: a systematic review of randomized, placebo-controlled trials and guidelines for clinical practice","volume":"26","author":"De Hert","year":"2011","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.arcped.2014.10.011_bib0115","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.neurenf.2009.09.004","article-title":"Principes de surveillances des effets m\u00e9taboliques, de l\u2019hyperprolactin\u00e9mie et du rythme cardiaque pour les antipsychotiques atypiques chez l\u2019enfant et l\u2019adolescent","volume":"58","author":"Bonnot","year":"2010","journal-title":"Neuropsychiatr Enfance Adolesc"},{"key":"10.1016\/j.arcped.2014.10.011_bib0120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/cap.2008.007","article-title":"Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents","volume":"19","author":"Calarge","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.arcped.2014.10.011_bib0125","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second generation antipsychotic medications during first-time use in children and adolescents","volume":"28","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.arcped.2014.10.011_bib0130","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1089\/cap.2006.0037","article-title":"Body Mass Indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics","volume":"17","author":"Patel","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.arcped.2014.10.011_bib0135","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pharmthera.2012.04.003","article-title":"Cardiovascular side effects of antipsychotic drugs: the role of the autonomic nervous system","volume":"135","author":"Leung","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.arcped.2014.10.011_bib0140","first-page":"26","article-title":"Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents","volume":"69","author":"Correll","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.arcped.2014.10.011_bib0145","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/cap.2008.0120","article-title":"Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects","volume":"19","author":"Roke","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.arcped.2014.10.011_bib0150","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/cap.2006.16.317","article-title":"The effect of long-term antipsychotic treatment on prolactine","volume":"16","author":"Staller","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.arcped.2014.10.011_bib0155","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/cap.2010.0079","article-title":"Children and adolescents with severe mental illness need vitamin D supplementation regardless of disease or treatment","volume":"21","author":"Bonnot","year":"2011","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.arcped.2014.10.011_bib0160","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/JCP.0b013e3182549259","article-title":"Adverse effects of second generation antipsychotics in children and adolescents: a Bayesian meta-analysis","volume":"32","author":"Cohen","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.arcped.2014.10.011_bib0165","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archpediatrics.2010.48","article-title":"Metabolic screening in children receiving antipsychotic drug treatment","volume":"164","author":"Morrato","year":"2010","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.arcped.2014.10.011_bib0170","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chc.2005.08.007","article-title":"Recognizing and monitoring adverse events of second generation antipsychotics in children and adolescents","volume":"15","author":"Correll","year":"2006","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"10.1016\/j.arcped.2014.10.011_bib0175","first-page":"128","article-title":"Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other","volume":"19","author":"Fleischhacker","year":"2006","journal-title":"Curr Opin Psychiatr"},{"key":"10.1016\/j.arcped.2014.10.011_bib0180","first-page":"3","article-title":"Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth","volume":"20","author":"Ho","year":"2011","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.arcped.2014.10.011_bib0185","first-page":"3","article-title":"Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth","volume":"20","author":"Pringsheim","year":"2011","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.arcped.2014.10.011_bib0190","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.encep.2009.10.008","article-title":"Effets secondaires m\u00e9taboliques de la risperidone dans les schizophr\u00e9nies \u00e0 d\u00e9but pr\u00e9coce","volume":"36","author":"Goeb","year":"2010","journal-title":"Encephale"},{"key":"10.1016\/j.arcped.2014.10.011_bib0195","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0447.1996.tb09814.x","article-title":"Catatonia. I. Rating scale and standardized examination","volume":"93","author":"Bush","year":"1996","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.arcped.2014.10.011_bib0200","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.schres.2005.01.014","article-title":"Clinical relevance of chronic catatonic schizophrenia in children and adolescents: evidence from a prospective naturalistic study","volume":"76","author":"Cohen","year":"2005","journal-title":"Schizoph Res"},{"issue":"Suppl 1","key":"10.1016\/j.arcped.2014.10.011_bib0205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.encep.2012.08.007","article-title":"Suivi th\u00e9rapeutique d\u2019un adolescent de 16ans souffrant de schizophr\u00e9nie pr\u00e9coce avec sympt\u00f4mes catatoniques","volume":"39","author":"Menard","year":"2013","journal-title":"Encephale"},{"key":"10.1016\/j.arcped.2014.10.011_bib0210","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.encep.2009.01.006","article-title":"Catatonie chez une adolescente de 14ans\u00a0: traitement par cloraz\u00e9pam et carbamaz\u00e9pine et \u00e9volution \u00e0 dix ans","volume":"36","author":"Ask\u00e9nazy","year":"2010","journal-title":"Encephale"},{"key":"10.1016\/j.arcped.2014.10.011_bib0215","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.rpsm.2012.03.006","article-title":"Secondary effects of antipsychotic treatment in na\u00efve or quasi-na\u00efve children and adolescents: design of a follow-up protocol and baseline results","volume":"5","author":"Merch\u00e1n-Naranjo","year":"2012","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"10.1016\/j.arcped.2014.10.011_bib0220","first-page":"60","article-title":"Olanzapine versus placebo in adolescents with schizophrenia: a 6\u00a0week, randomized, double-blind, placebo-controlled trial","volume":"48","author":"Kryzhanovskaya","year":"2009","journal-title":"Psychiatry"},{"key":"10.1016\/j.arcped.2014.10.011_bib0225","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1399-5618.2009.00750.x","article-title":"Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study","volume":"11","author":"Haas","year":"2009","journal-title":"Bipolar Disord"},{"issue":"Suppl 4","key":"10.1016\/j.arcped.2014.10.011_bib0230","first-page":"9","article-title":"Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents","volume":"69","author":"Findling","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.arcped.2014.10.011_bib0235","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jama.292.7.807","article-title":"Fluox\u00e9tine, cognitive-behavioral therapy, and their combination for adolescents with depression. Treatment for Adolescent with Depression Study (TADS). Randomized controlled trial","volume":"292","author":"March","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.arcped.2014.10.011_bib0240","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00004583-200405000-00004","article-title":"The child and adolescent psychiatry trials network (CAPTN)","volume":"43","author":"Shapiro","year":"2004","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.arcped.2014.10.011_bib0245","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neurenf.2013.01.004","article-title":"\u00c9valuation de l\u2019incidence des \u00e9v\u00e9nements ind\u00e9sirables sous antipsychotique en population p\u00e9diatrique na\u00efve (\u00c9tude ETAPE\u00a0: \u00c9tude de la Tol\u00e9rance des AntiPsychotiques chez l\u2019Enfant)","volume":"61","author":"Menard","year":"2013","journal-title":"Neuropsychiatr Enfance Adolesc"},{"key":"10.1016\/j.arcped.2014.10.011_bib0250","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.encep.2013.03.005","article-title":"S\u00e9curiser la prescription des antipsychotiques en population p\u00e9diatrique\u00a0: une \u00e9tude multicentrique fran\u00e7aise en population na\u00efve","volume":"39","author":"Menard","year":"2013","journal-title":"Encephale"}],"container-title":["Archives de P\u00e9diatrie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929693X14004837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929693X14004837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T21:51:50Z","timestamp":1538085110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929693X14004837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0929693X14004837"],"URL":"https:\/\/doi.org\/10.1016\/j.arcped.2014.10.011","relation":{},"ISSN":["0929-693X"],"issn-type":[{"value":"0929-693X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Am\u00e9liorer la surveillance de la tol\u00e9rance p\u00e9diatrique des antipsychotiques en France","name":"articletitle","label":"Article Title"},{"value":"Archives de P\u00e9diatrie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcped.2014.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}